Suppr超能文献

酒精使用障碍治疗的药物遗传学:更新。

Pharmacogenetics of alcohol use disorder treatments: an update.

机构信息

a Mental Illness Research, Education and Clinical Center , Crescenz VAMC , Philadelphia , PA , USA.

b Center for Studies of Addiction, Department of Psychiatry , University of Pennsylvania Perelman School of Medicine , Philadelphia , PA , USA.

出版信息

Expert Opin Drug Metab Toxicol. 2019 Jul;15(7):553-564. doi: 10.1080/17425255.2019.1628218. Epub 2019 Jun 11.

Abstract

: Alcohol use disorder (AUD) is highly prevalent; costly economically, socially, and interpersonally; and grossly undertreated. The low rate of utilization of medications with demonstrated (albeit modest) efficacy is particularly noteworthy. One approach to increasing the utility and safety of available medications is to use a precision medicine approach, which seeks to identify patients for whom specific medications are likely to be most efficacious and have the fewest adverse effects. : We review the literature on the pharmacogenetics of AUD treatment using both approved and off-label medications. We cover both laboratory studies and clinical trials, highlighting valuable mechanistic insights and underscoring the potential value of precision-based care for AUD. : Pharmacotherapy can be a useful component of AUD treatment. Currently, the evidence regarding genetic predictors of medication efficacy is very limited. Thus, a precision medicine approach is not yet ready for widespread clinical implementation. Further research is needed to identify candidate genetic variants that moderate the response to both established and novel medications. The growing availability of large-scale, longitudinal datasets that enable the synthesis of genetic and electronic health record data provides important opportunities to develop this area of research.

摘要

酒精使用障碍(AUD)的患病率很高;在经济、社会和人际关系方面造成了巨大的损失,但治疗率却很低。特别值得注意的是,具有已证实(尽管适度)疗效的药物的利用率很低。增加现有药物的实用性和安全性的一种方法是采用精准医学方法,这种方法旨在确定特定药物最有可能对哪些患者有效,且副作用最少。

我们使用已批准和非标签药物综述了 AUD 治疗的药物遗传学文献。我们涵盖了实验室研究和临床试验,突出了有价值的机制见解,并强调了基于精准的 AUD 护理的潜在价值。

药物治疗可以成为 AUD 治疗的有用组成部分。目前,关于药物疗效遗传预测因子的证据非常有限。因此,精准医学方法尚未准备好广泛应用于临床。需要进一步研究以确定候选基因变异,这些基因变异可以调节对既定和新型药物的反应。越来越多的大规模、纵向数据集的出现,使基因和电子健康记录数据的综合成为可能,为这一研究领域提供了重要机会。

相似文献

1
Pharmacogenetics of alcohol use disorder treatments: an update.
Expert Opin Drug Metab Toxicol. 2019 Jul;15(7):553-564. doi: 10.1080/17425255.2019.1628218. Epub 2019 Jun 11.
2
Pharmacotherapies and personalized medicine for alcohol use disorder: a review.
Pharmacogenomics. 2020 Oct;21(15):1117-1138. doi: 10.2217/pgs-2020-0079. Epub 2020 Aug 18.
3
Pharmacotherapy for alcohol dependence: A stratified approach.
Pharmacol Ther. 2015 Sep;153:10-24. doi: 10.1016/j.pharmthera.2015.05.010. Epub 2015 May 16.
4
Personalized Medicine of Alcohol Addiction: Pharmacogenomics and Beyond.
Curr Pharm Biotechnol. 2017;18(3):221-230. doi: 10.2174/1389201018666170224105025.
5
Pharmacotherapy for Alcohol Use Disorder.
Med Clin North Am. 2018 Jul;102(4):653-666. doi: 10.1016/j.mcna.2018.02.008. Epub 2018 Apr 26.
6
Pharmacotherapy of alcoholism - an update on approved and off-label medications.
Expert Opin Pharmacother. 2017 Aug;18(12):1187-1199. doi: 10.1080/14656566.2017.1349098. Epub 2017 Jul 24.
7
Pharmacogenetics of alcohol use disorders and comorbid psychiatric disorders.
Psychiatry Res. 2015 Dec 15;230(2):121-9. doi: 10.1016/j.psychres.2015.09.019. Epub 2015 Sep 14.
8
Review: Pharmacogenetics of alcoholism treatment: Implications of ethnic diversity.
Am J Addict. 2017 Aug;26(5):516-525. doi: 10.1111/ajad.12463. Epub 2016 Nov 4.
9
Alcohol addiction - the safety of available approved treatment options.
Expert Opin Drug Saf. 2018 Feb;17(2):169-177. doi: 10.1080/14740338.2018.1404025. Epub 2017 Nov 20.

引用本文的文献

1
Investigating Therapeutic Targets for Alcohol Use Disorder: Pharmacological View of ClinicalTrials.gov Data.
Int J Gen Med. 2025 Jul 4;18:3701-3712. doi: 10.2147/IJGM.S530721. eCollection 2025.
2
Moderation of treatment outcomes by polygenic risk for alcohol-related traits in placebo-controlled trials of topiramate.
Alcohol Clin Exp Res (Hoboken). 2025 Jun;49(6):1297-1305. doi: 10.1111/acer.70052. Epub 2025 May 30.
3
Next-generation biomarkers for alcohol consumption and alcohol use disorder diagnosis, prognosis, and treatment: A critical review.
Alcohol Clin Exp Res (Hoboken). 2025 Jan;49(1):5-24. doi: 10.1111/acer.15476. Epub 2024 Nov 12.
4
The genetic landscape of substance use disorders.
Mol Psychiatry. 2024 Nov;29(11):3694-3705. doi: 10.1038/s41380-024-02547-z. Epub 2024 May 29.
5
Hovenia dulcis: a Chinese medicine that plays an essential role in alcohol-associated liver disease.
Front Pharmacol. 2024 Apr 8;15:1337633. doi: 10.3389/fphar.2024.1337633. eCollection 2024.
6
Association of Alcohol Use Disorder Risk With , and Genetic Polymorphisms.
In Vivo. 2022 Sep-Oct;36(5):2092-2104. doi: 10.21873/invivo.12935.
7
Targeting Unmet Clinical Needs in the Treatment of Alcohol Use Disorder.
Front Psychiatry. 2022 Jun 9;13:767506. doi: 10.3389/fpsyt.2022.767506. eCollection 2022.
8
Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study.
Neuropsychopharmacology. 2021 Nov;46(12):2132-2139. doi: 10.1038/s41386-021-01097-0. Epub 2021 Jul 23.
9
Combined analysis of the moderating effect of a GRIK1 polymorphism on the effects of topiramate for treating alcohol use disorder.
Drug Alcohol Depend. 2021 Aug 1;225:108762. doi: 10.1016/j.drugalcdep.2021.108762. Epub 2021 May 21.
10
Applying methods for personalized medicine to the treatment of alcohol use disorder.
J Consult Clin Psychol. 2021 Apr;89(4):288-300. doi: 10.1037/ccp0000634.

本文引用的文献

1
Transancestral GWAS of alcohol dependence reveals common genetic underpinnings with psychiatric disorders.
Nat Neurosci. 2018 Dec;21(12):1656-1669. doi: 10.1038/s41593-018-0275-1. Epub 2018 Nov 26.
2
Baclofen for the treatment of alcohol use disorder: the Cagliari Statement.
Lancet Psychiatry. 2018 Dec;5(12):957-960. doi: 10.1016/S2215-0366(18)30303-1. Epub 2018 Nov 6.
4
Baclofen in the Treatment of Patients With Alcohol Use Disorder and Other Mental Health Disorders.
Front Psychiatry. 2018 Sep 28;9:464. doi: 10.3389/fpsyt.2018.00464. eCollection 2018.
5
Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review.
JAMA. 2018 Aug 28;320(8):815-824. doi: 10.1001/jama.2018.11406.
7
Investigational drug therapies in phase I and phase II clinical trials for alcohol use disorders.
Expert Opin Investig Drugs. 2018 Jul 27:1-14. doi: 10.1080/13543784.2018.1502269.
8
Moderation of baclofen response by a GABA receptor polymorphism: results from the BacALD randomized controlled trial.
Addiction. 2018 Dec;113(12):2205-2213. doi: 10.1111/add.14373. Epub 2018 Jul 24.
9
Biosignature Discovery for Substance Use Disorders Using Statistical Learning.
Trends Mol Med. 2018 Feb;24(2):221-235. doi: 10.1016/j.molmed.2017.12.008. Epub 2018 Feb 4.
10
Pharmacogenetic Effects of Naltrexone in Individuals of East Asian Descent: Human Laboratory Findings from a Randomized Trial.
Alcohol Clin Exp Res. 2018 Mar;42(3):613-623. doi: 10.1111/acer.13586. Epub 2018 Feb 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验